Sustained-release suspension for treating glaucoma and preparation method thereof

A slow-release suspension, glaucoma technology, applied in the field of medicine, can solve problems such as low bioavailability, and achieve the effects of drug safety, improved bioavailability and definite curative effect

Inactive Publication Date: 2013-12-11
ZHENGZHOU UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of the above situation, in order to solve the defects of the prior art, the object of the present invention is to provide a slow-release suspension for the treatment of glaucoma and its preparation method, which can effectively solve the problem of low bioavailability in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained-release suspension for treating glaucoma and preparation method thereof
  • Sustained-release suspension for treating glaucoma and preparation method thereof
  • Sustained-release suspension for treating glaucoma and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The suspension is calculated by the following weight percentages: timolol maleate 1.5-2.5%, IRP-69 cation exchange resin 2.6-4.5%, microcapsule coating material 0.2-5%, plasticizer 6- 9%, impregnating agent 3.5-4%, suspending agent 9-17%, osmotic pressure regulator 0.2-4.5%, preservative 0.001-0.009%, pH regulator 0.2-5%, sorbitan monooleate 1.5% ~9%, liquid paraffin 11~20%, microcapsule coating material solvent 11~20% and ultrapure water 30~40%.

Embodiment 2

[0022] The suspension is calculated by the following percentages by weight: timolol maleate 3-4.5%, IRP-69 cation exchange resin 1.5-2.5%, microcapsule coating material 6-9%, plasticizer 0.2- 5%, impregnating agent 5-9%, suspending agent 0.2-8%, osmotic pressure regulator 5-9%, preservative 0.01-0.015%, pH regulator 6-9%, sorbitan monooleate 10% ~18%, liquid paraffin 5.5~10%, microcapsule coating material solvent 1.5~10% and ultrapure water 41~55%.

Embodiment 3

[0024] The suspension is calculated by the following weight percentages: timolol maleate 4%, IRP-69 cation exchange resin 2%, ethyl cellulose 2%, diethyl phthalate 5%, methyl Cellulose 3%, hydroxypropyl methylcellulose 5%, borax 3%, boric acid 3%, benzalkonium bromide 0.01%, triethylamine solution 5%, sorbitan monooleate 5%, liquid paraffin 20 %, absolute ethanol 10% and ultrapure water 32.99%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a sustained-release suspension for treating glaucoma and a preparation method thereof, effectively solving the problem of low bioavailability in the prior art. According to the technical scheme, the sustained-release suspension comprises the following components in percentage by weight: 1.0-5.0 percent of timolol maleate, 1.0-5.0 percent of IRP-69 cation exchange resin, 0.1-10 percent of a micro-capsule coating material, 0.1-10 percent of plasticizer, 3-10 percent of impregnant, 0.1-20 percent of suspending agent, 0.1-10 percent of osmotic pressure regulator, 0.001-0.02 percent of preservative, 0.1-10 percent of pH regulator, 1.0-20 percent of sorbitan monooleate, 5-50 percent of liquid paraffin, 1.0-50 percent of micro-capsule coating material solvent, and 30-70 percent of super-pure water. The sustained-release suspension is safe in administration and definite in curative effect, does not have irritation, can remarkably improve the bioavailability of timolol maleate, and is an innovation in the field of medicine for treating glaucoma.

Description

technical field [0001] The invention relates to medicine, in particular to a slow-release suspension for treating glaucoma and a preparation method thereof. Background technique [0002] Glaucoma is an eye disease in which intraocular pressure is intermittently or continuously elevated. It is named so because the pupils are more or less turquoise. Sustained high intraocular pressure can cause damage to various parts of the eyeball and visual function. If it is not treated in time, the visual field can be completely lost and even blind. Glaucoma is one of the three major blindness diseases that cause blindness in humans. The incidence rate is about 0.21% to 1.64%, and it is as high as 3.5% for people over 40 years old. It has been reported that "there are more than 5 million glaucoma patients in China, of which 790,000 are blind, and two out of every 100 people over the age of 50 suffer from glaucoma." Treating glaucoma is currently a challenge for ophthalmologists. [00...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/10A61K31/5377A61P27/06
Inventor 刘伟胡海英辛红霞曹晶晶秦芙红李恒
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap